EN DE
STOCK COMPARISON

FDC vs Jiangsu Hengrui Medicine Co: Fair Value & Quality

Both stocks run through our valuation models. Here is how FDC (FDC) and Jiangsu Hengrui Medicine Co (600276) compare, as of Aug 10, 2026.

As of Aug 10, 2026, Fair Value Calculator sees FDC as the less overvalued of the two: FDC trades at ₹370 versus a fair value of ₹209 (-43%), while Jiangsu Hengrui Medicine Co trades at ¥54.62 versus ¥25.94 (-53%).
FDC
FDC.NSE · INR · Health Care
-43%
upside to fair value
overvalued
Price₹370
Fair Value₹209
Quality58/100
Jiangsu Hengrui Medicine Co
600276.SHG · CNY · Health Care
-53%
upside to fair value
overvalued
Price¥54.62
Fair Value¥25.94
Quality66/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

FDCJiangsu Hengrui Medicine Co
Valuation
23.6×P/E (TTM)43.6×
3.06×P/S (TTM)10.84×
2.67×P/B5.76×
19.0×EV/EBITDA33.0×
—PEG0.93×
1.2%Dividend yield0.4%
₹5.00Dividend per share¥0.20
Profitability
13%Net margin25%
16%Operating margin32%
12%Return on equity15%
6%Return on assets9%
Growth
19%Revenue growth (YoY)13%
6.8%Avg. growth/yr (3Y)13.9%
10.3%Avg. growth/yr (5Y)2.5%
Balance & size
$697MMarket cap$52B
expensiveGrowth qualityhealthy

FDC leads: 7 to 5 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

FDCof which business quality 57 · market factors 45 Jiangsu Hengrui Medicine Coof which business quality 68 · market factors 46
ProfitabilityMargins and returns on capital today
55
63
Quality GrowthAre margins and returns improving?
39
41
CashflowEarnings quality: real cash, not paper profit
25
82
Fin. StrengthBalance sheet, leverage, solvency risk
81
100
InvestmentDisciplined investing over empire-building
62
27
Low VolatilityCalm price path (market factor)
83
78
MomentumPrice trend over the last 3–12 months (market factor)
37
35
52W MomentumDistance to the 52-week high (market factor)
17
29
Net IssuanceBuybacks instead of dilution
84
64

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

FDC

DCF Models₹221
Earnings-Based₹154
Dividend Discount₹87.56
Multiples₹297
Asset-Based₹102
Growth DCF₹149
Economic Profit₹148
Growth Earnings₹290

24 of 26 models see the stock below the current price.

Jiangsu Hengrui Medicine Co

DCF Models¥37.78
Earnings-Based¥21.29
Dividend Discount¥3.82
Multiples¥23.65
Asset-Based¥6.44
Growth DCF¥39.88
Economic Profit¥18.21
Growth Earnings¥30.99

26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

FDC
Bear ₹133Fair Value ₹209Bull ₹336
₹370 = current price (white tick)
Jiangsu Hengrui Medicine Co
Bear ¥19.95Fair Value ¥25.94Bull ¥40.28
¥54.62 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

FDC · Health Care

Quality score58 · above median
Fair value upside-43% · below median

Jiangsu Hengrui Medicine Co · Health Care

Quality score66 · Top 25%
Fair value upside-53% · below median

Bottom line

As of Aug 10, 2026, Fair Value Calculator sees FDC as the less overvalued of the two: FDC trades at ₹370 versus a fair value of ₹209 (-43%), while Jiangsu Hengrui Medicine Co trades at ¥54.62 versus ¥25.94 (-53%).

Jiangsu Hengrui Medicine Co has the higher quality score (66/100).

See the full analysis →
FDC · Jiangsu Hengrui Medicine Co

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to FDC

Eli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupAbbVie vs UnitedHealth GroupUnitedHealth Group vs Merck & Company

Related to Jiangsu Hengrui Medicine Co

UnitedHealth Group vs AstraZenecaUnitedHealth Group vs Thermo Fisher ScientificUnitedHealth Group vs AmgenUnitedHealth Group vs Abbott Laboratories
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.